Phenotype Annotations Click to see Annotation Detail View
Mammalian PhenotypeTerm | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | decreased circulating prolactin level | induced | IAGP | 17 beta-estradiol | 2292503; 2292503 | compared to ACI/SegHsd | RGD | | decreased circulating prolactin level | induced | IAGP | 17 beta-estradiol | 2292503 | compared to ACI/SegHsd | RGD | | decreased mammary gland tumor incidence | | IDA | | 2292503 | | RGD | | decreased pituitary gland weight | induced | IAGP | 17 beta-estradiol | 2292503 | compared to ACI/SegHsd | RGD | | decreased pituitary gland weight | induced | IAGP | 17 beta-estradiol | 2292503 | compared to ACI/SegHsd | RGD | | decreased thymus weight | | IAGP | | 2292503 | compared to COP/CrCrl and ACI/SegHsd | RGD | | decreased thymus weight | | IAGP | | 2292503; 2292503 | compared to COP/CrCrl | RGD | | decreased thymus weight | | IAGP | 17 beta-estradiol | 2292503 | compared to COP/CrCrl and ACI/SegHsd | RGD | | decreased thymus weight | induced | IAGP | 17 beta-estradiol | 2292503 | compared to ACI/SegHsd | RGD | | decreased tumor growth/size | induced | IAGP | 17 beta-estradiol | 2292503 | compared to ACI/SegHsd | RGD | | increased circulating prolactin level | induced | IAGP | 17 beta-estradiol | 2292503 | compared COP/CrCrl | RGD | | increased circulating prolactin level | induced | IAGP | 17 beta-estradiol | 2292503; 2292503 | compared to COP/CrCrl | RGD | | increased mammary gland tumor incidence | induced | IAGP | 17 beta-estradiol | 2292503 | compared to ACI.COP-D6Rat80-D6Rat146/Shul�� | RGD | | increased pituitary gland weight | induced | IAGP | 17 beta-estradiol | 2292503 | compared COP/CrCrl | RGD | | increased pituitary gland weight | induced | IAGP | 17 beta-estradiol | 2292503 | compared to ACI/SegHsd and COP/CrCrl | RGD | | increased pituitary gland weight | induced | IAGP | 17 beta-estradiol | 2292503 | compared to untreated COP/CrCrl | RGD | | increased pituitary gland weight | induced | IAGP | 17 beta-estradiol | 2292503 | compared to COP/CrCrl | RGD | | increased thymus weight | induced | IAGP | 17 beta-estradiol | 2292503 | compared to COP/CrCrl | RGD | | increased thymus weight | | IAGP | | 2292503 | compared to ACI/SegHsd | RGD | | increased tumor latency | induced | IAGP | 17 beta-estradiol | 2292503 | compared to ACI/SegHsd more ... | RGD | | pituitary gland hyperplasia | | IDA | | 2292503; 2292503; 2292503; 2292503 | E2 induced for 12 weeks | RGD | | thymus atrophy | | IDA | | 2292503 | E2 induced for 12 weeks | RGD | | |